论文部分内容阅读
1986年12月到1995年6月共收治中晚期前列腺癌45例，均经病理证实。按Jewett分期：C期17例、D1期6例、D2期22例。治疗采用在去势治疗基础上，以放射治疗、内分泌治疗以及对D2期骨转移的部分病人同时用骨增综合治疗。结果显示：1、3年生存率分别为97．8％、57.6％、C期5年生存率达60％。放射治疗对于C期及D1期是一种有效的治疗，8MV－X和18MV－X射线照射，DT60～75Gy／6～8周。D2期大部分以缓退瘤治疗，每日口服750mg，连续2～3月，症状改善和客观效应均较理想。有骨转移者采用转移灶止病性放疗及配合缓退瘤、骨腾治疗，症状改善及转移灶稳定或消失，副作用小。
From December 1986 to June 1995, 45 cases of advanced prostate cancer were admitted, all confirmed by pathology. According to Jewett staging: C period in 17 cases, D1 in 6 cases, D2 in 22 cases. Treatment is based on the castration treatment, radiation therapy, endocrine therapy and D2 patients with bone metastases at the same time with bone augmentation treatment. The results showed that the 1-year and 3-year survival rates were 97.8% and 57.6%, respectively, and the 5-year survival rate of C was 60%. Radiation therapy for C and D1 is an effective treatment, 8MV-X and 18MV-X-ray irradiation, DT60 ~ 75Gy / 6 ~ 8 weeks. The majority of D2 patients treated with withdrawal therapy, oral administration of 750mg daily for 2 to 3 months, the symptoms and objective effects are better. Patients with bone metastases using metastatic disease radiotherapy and with cachexia, bone treatment, the symptoms improve and metastasis stable or disappear, with little side effects.